Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants

BACKGROUND: Antibody–drug conjugates (ADC), such as enfortumab vedotin (EV), sacituzumab govitecan (SG), and RC-48, have shown outstanding response rates to local advanced or metastatic urothelial carcinoma (UC). However, their corresponding target expression characteristics in UC and its histologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yu, Li, Qinhan, Shen, Qi, Liu, Zhifu, Zhang, Zhenan, Hu, Shuai, Yu, Wei, He, Zhisong, He, Qun, Zhang, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063095/
https://www.ncbi.nlm.nih.gov/pubmed/35515131
http://dx.doi.org/10.3389/fonc.2022.858865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063095/
https://www.ncbi.nlm.nih.gov/pubmed/35515131
http://dx.doi.org/10.3389/fonc.2022.858865

Ejemplares similares